Rénibus Therapeutics Stock

www.renibus.comHealthcare / BioTech & PharmaFounded: 2015

Rénibus Therapeutics is a biopharmaceutical and technology company with a mission to prevent disease progression in patients with metabolic or cardiovascular diseases. As a clinical-stage healthcare company, Rénibus Therapeutics is also working on developing an RBT-1 drug which aims to decrease post-operative complications in heart surgery patients or patients with kidney disease. Rénibus Therapeutics was founded by Alvaro Guillem and D. Jeffrey Keyser in 2016 and is headquartered in Southlake, TX.

Register To Buy and Sell Shares

For more details on financing and valuation for Rénibus Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Rénibus Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Rénibus Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Rénibus Therapeutics investors also invested in these private companies


Management Team

Alvaro Guillem Ph.D
Jamie Donadio
Chief Financial Officer

Rénibus Therapeutics’ stock FAQs


Can you buy Rénibus Therapeutics’ stock?

Rénibus Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy Rénibus Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.

Can you sell Rénibus Therapeutics’ stock?

Yes, you can sell stock of a private company like Rénibus Therapeutics. Forge can help you sell your Rénibus Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.

What is Rénibus Therapeutics’ stock price?

Rénibus Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access Rénibus Therapeutics’ private market stock price with Forge Data.

What is Rénibus Therapeutics’ stock ticker symbol?

Rénibus Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Renibus Therapeutics Announces Final Close of Upsized Series B Financing, Bringing Total Round to $72 Million

Renubus raised $72 million in a series b funding round.
Updated on: Jul 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.